Critical

Tumour lysis syndrome

Oncologic metabolic · Metabolic
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Massive tumour cell breakdown (spontaneous or post-chemotherapy) releasing potassium, phosphate and urate — causing hyperkalaemia, hyperphosphataemia, hypocalcaemia and AKI.

Red flags

  • Hyperkalaemia with ECG changes
  • Oliguric AKI
  • Symptomatic hypocalcaemia (tetany/seizure)
  • Arrhythmia

Assessment

Differential diagnosis

  • Rhabdomyolysis
  • AKI (other cause)
  • Primary hyperkalaemia
  • Sepsis with organ dysfunction

Investigations

  • U&E, potassium, phosphate, calcium, urate, LDH
  • ECG (hyperkalaemia), VBG
  • FBC; identify malignancy/treatment timing
  • Cairo-Bishop criteria

Management

  • Aggressive IV hydration to maintain urine output
  • Treat hyperkalaemia urgently (calcium, insulin-dextrose, salbutamol) — cardiac monitor
  • Rasburicase for high urate (or allopurinol for prevention/lower risk)
  • Avoid IV calcium for hypocalcaemia unless symptomatic (worsens phosphate precipitation)
  • Renal/oncology referral; dialysis for refractory hyperkalaemia or severe AKI

Drugs & doses

IV crystalloid
Rasburicase (or allopurinol)
Hyperkalaemia therapy

Disposition

Admit; HDU/ICU; oncology + renal.

Complications & pitfalls

  • Life-threatening hyperkalaemia
  • AKI
  • Arrhythmia, seizures

Exam pearls

  • Hydration + rasburicase are the key prophylaxis and treatment
  • Avoid giving calcium for asymptomatic hypocalcaemia (calcium-phosphate precipitation)
  • Rasburicase is contraindicated in G6PD deficiency

Hydrate hard, treat hyperkalaemia, lower urate with rasburicase, and involve renal early.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.